Takeda hitting 2013 ASH with Abstracts on Velcade, Adcetris, more

Takeda Pharmaceutical Company Limited is announcing that 370 abstracts, featuring five molecules in the company's portfolio, have been accepted for presentation at this year's American Society of Hematology (ASH) annual meeting to be held in New Orleans in December.

Notably, the abstracts will include presentations for two key lymphoma drugs: Velcade (bortezomib) for injection, and Adcetris (brentuximab vedotin). The abstracts will also include three of the company's pipeline agents, including MLN9708, the first oral proteasome inhibitor to enter Phase 3 development.

Data presentations

Presentations on Velcade include an analysis of overall survival (OS) from the VISTA trial in previously untreated multiple myeloma (MM). Other presentations will feature new Phase II data on MLN9708 and the long-term survival updates for Adcetris in relapsed/refractory Hodgkin's lymphoma and relapsed/refractory Anaplastic Large Cell Lymphoma.

Said Michael Vasconcelles, M.D., Head, Oncology Therapeutic Area Unit, Takeda:

The updated overall survival results for Velcade and Adcetris to be presented at this year's ASH will be important data for patients with Multiple Myeloma and relapsed or refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma, respectively. Data for these products, as well as agents in the Takeda pipeline such as MLN9708, are providing meaningful insights in defining optimal therapy for a wide range of hematologic malignancies.

The American Society of Hematology (ASH) meeting is taking place December 7-10 in New Orleans.

Source: Takeda